This paper outlines new challenges that are making it more difficult for biopharma companies to optimize returns on investments in new therapies. Based on an analysis of nearly 300 launches, it seeks to identify the factors that are most closely related to commercial success, as well as the key causes of failure. Finally, it outlines a framework that decision-makers can use to maximize any asset’s likelihood of commercial success.
